pyrazines has been researched along with Uterine Cervical Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC | 1 |
| Bambi, F; Barti-Juhasz, H; Bussolari, R; Cafarelli, L; Casali, C; Conte, P; De Santis, G; Dominici, M; Frassoldati, A; Grisendi, G; Horwitz, EM; Morandi, U; Paolucci, P; Petak, I; Rasini, V; Rossi, G; Scarabelli, L; Spano, C; Tagliazzucchi, M; Veronesi, E | 1 |
| Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M | 1 |
| Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T | 1 |
| Brem, GJ; Brüning, A; Mylonas, I | 1 |
| Akatsuka, Y; Ito, K; Ito, Y; Iwata, K; Kiyono, T; Kodera, Y; Kondo, E; Kuzushima, K; Morishima, S; Morishima, Y; Nakanishi, T; Nawa, A; Takahashi, T; Torikai, H; Tsujimura, K | 1 |
| Birle, DC; Hedley, DW | 1 |
| Lin, ZH | 1 |
| Dicker, AP; Kamer, S; Ren, Q | 1 |
1 review(s) available for pyrazines and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
[Issues related to basic research on uterine and ovarian tumor pathology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Human papillomavirus 16; Humans; Ovarian Neoplasms; Papillomavirus Infections; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Trastuzumab; Tumor Suppressor Protein p53; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms | 2007 |
9 other study(ies) available for pyrazines and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms | 2014 |
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Topics: Adipocytes; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Communication; Coculture Techniques; Enzyme Activation; Female; HeLa Cells; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Pyrazines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Transduction, Genetic; Uterine Cervical Neoplasms | 2010 |
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carboplatin; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uterine Cervical Neoplasms | 2013 |
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum Stress; Female; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Membrane Potential, Mitochondrial; Pyrazines; Transcription Factor CHOP; Ubiquitin; Up-Regulation; Uterine Cervical Neoplasms | 2013 |
News & views in ... Immunotherapy.
Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines | 2012 |
Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Topics: Adult; Amino Acid Sequence; Animals; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Drug Synergism; Epitopes, T-Lymphocyte; Female; Flow Cytometry; Gene Expression; HLA-A Antigens; HLA-A24 Antigen; Humans; Interferon-gamma; Mice; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Viral; Protease Inhibitors; Pyrazines; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Cytotoxic; Uterine Cervical Neoplasms | 2007 |
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; E1A-Associated p300 Protein; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; Male; Prostatic Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Survival; Female; HeLa Cells; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 2009 |